BeOne Medicines reported positive topline Phase 1/2 data for sonrotoclax, a BCL2 inhibitor targeting mantle cell lymphoma, an aggressive blood cancer subtype. The candidate met the primary endpoint of overall response rate with acceptable safety. These results underpin BeOne’s strategy to pursue accelerated regulatory approval and address unmet medical needs in rare lymphomas. The company aims to leverage this momentum to file for approval and expand therapeutic options for patients lacking effective treatments.